SEC Form 4 · accession 0001615774-18-010439
ANAVEX LIFE SCIENCES CORP. · AVXL
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Sandra Boenisch
Officer — PFO & Treasurer
Period of report
Oct 1, 2018
Accepted (ET)
Oct 3, 2018 · 5:29 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001314052
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $2.58 | Oct 1, 2018 | A | 27,300 | A | — | Oct 1, 2028 | Common Stock | 27,300 | 27,300 | D |
Explanation of responses
- F1The options shall vest upon the achievement of 50% enrollment in the Company's Alzheimer's disease and Parkinson's disease dementia clinical trials.